Skip to main content

Table 1 Shantha Timeline

From: Indian vaccine innovation: the case of Shantha Biotechnics

Year

Milestone

1992

Dr. Varaprasad attends immunization conference in Geneva; Hep-B idea forms

1993

Shantha Biotechnics is born, staff works out of Osmania University

1994

Shantha Biotechnics moves to Centre for Cellular and Molecular Biology

1995

Oman invests $1.2 million in equity; Shantha moves into own facility

1997

Shantha's Hepatitis B vaccine, Shanvac-B, launched (first recombinant health product in India)

1998

Shantha sells 22 million doses of Shanvac-B this year, far exceeding expectations

1999

Comparative study proving the high quality of Shanvac-B published in Vaccine

2000

Morgan Stanley and State Bank of Indian Mutual Fund invest $10 million in equity

2002

Shantha introduces first bio-therapeutic product, Interferon α 2b, onto the market

Shantha receives WHO pre-qualification for Shanvac-B

2005

Shantha introduces first combination vaccine onto market - Shantetra (diphtheria, pertussis, tetanus, hepatitis B)

2007

Merieux Alliance picks up 60% stake in Shantha, which it later expands to 80%

2009

Shantha wins a $340 M USD contract from UNICEF for pentavalent vaccines

 

Sanofi-Aventis acquires an 80% controlling stake valuing the firm at $784 M USD